2015 American Transplant Congress
Opportunities in Tacrolimus Therapeutic Drug Monitoring
Department of Pharmacy, NewYork-Presbyterian Hospital, NY.
Tacrolimus requires diligent therapeutic drug monitoring (TDM) to maintain appropriate serum concentrations after transplant. To optimize efficacy & minimize toxicity frequent levels are drawn, commonly…2015 American Transplant Congress
Impact of Type of Tacrolimus Assay on Therapeutic Drug Monitoring: Need for Standardization
Internal Medicine/Nephrology, Washington University School of Medicine, St. Louis, MO.
Background: Multiple assays are available for measuring tacrolimus (FK) levels and these are not currently standardized. A designated laboratory transitioned their FK assay from Enzyme…2015 American Transplant Congress
Prospective, 6 Month, Open Label, Conversion Study from Mycophenolate Mofetyl to Mycophenolic Acid Evaluating the Severity of Gastro-Intestinal Symptoms and Mycophenolic Acid Urinary Metabolite as a Surrogate Marker of Plasmatic Area Under the Curve
Introduction: Treatment with mycophenolate mofetil (MMF) often results in adverse gastro-intestinal (GI) events, which can lead to dose reductions that in turn can increase the…2015 American Transplant Congress
No Pharmacokinetic Interaction Between Pantoprazole and Mycophenolic Acid in Renal Transplant Patents: A Randomized Crossover Study
Department of Nephrology, Charité University Hospital, Berlin, Germany.
Mycophenolic acid (MPA) is used as an immunosuppressive agent in renal transplant (tx) patients (pts). 2 formulations are on the market: The prodrug Mycophenolate-Mofetil (MMF)…2015 American Transplant Congress
Clinical Outcomes of Kidney Transplan Recipients After Sirolimus Or Everolimus Conversion. Experience in a Single Center
Transplant Unit, Fundación Valle del Lili, Cali, Colombia.
Introduction. The use of m_TOR inhibitors sirolimus (SRL) and everolimus (EVL), in kidney transplant recipients (KTR) is an alternative immunosuppressive therapy to reduce or withdrawal…2015 American Transplant Congress
Belatacept in a Community Hospital Adult Kidney Transplant Program
Iowa Methodist Medical Center, Des Moines, IA.
PURPOSE:This is a retrospective look (08/2011-11/2014) on data collected from patients transplanted at Iowa Methodist Transplant Center.METHODS:All patients were EBV positive. They were induced with…2015 American Transplant Congress
Toxicity Driven Conversion to Belatacept in Kidney Transplant Recipients
Yale-New Haven Transplantation Center, New Haven, CT.
Purpose: Evaluate the result of conversion to belatacept from calcineurin inhibitor (CNI) or TOR inhibitor based regimens due to toxicities in kidney transplant recipients (KTR).Methods:…2015 American Transplant Congress
Belatacept Treatment Through Home Infusion as a Safe and Reasonable Alternative to Intitution-Based Treatment: A Retrospective Analysis of Medical Records
1Bristol-Myers Squibb Company, Princeton, NJ; 2BiologicTx, Totowa, NJ.
Purpose: Belatacept is a selective T-cell costimulation blocker indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant in combination with basiliximab…2015 American Transplant Congress
Medication Non-Adherence in Those Waiting for a Transplant
Purpose: Though poor medication adherence among adult kidney transplant patients is alarmingly high with distressing consequences, no one has systematically examined medication non-adherence in those…2015 American Transplant Congress
Kidney Transplant Outcomes in Marijuana Users
Introduction: As Marijuana use is gaining social acceptance, many transplant centers face questions regarding candidacy of users for kidney transplantation. Currently its impact on post-transplantation…
American Transplant Congress abstracts